¹**Title: Point-of-care lung ultrasound predicts severe disease and death due to COVID-19: a**

²**prospective cohort study.**

- **Authors:** Paul W. Blair, $MD^{1,2^*,**}$, Trishul Siddharthan, $MD^{3,4^{**}}$, Gigi Liu, MD^5 , Jiawei Bai,
- 4 PhD⁶, Joshua East, RPSGT⁴, Phabiola Herrera, MD³, Lalaine Anova, MS¹, Varun Mahadevan⁴,
- 5 Shakir Hossen, MBBS⁴, Stefanie Seo, BS⁷, Olamide Sonuga, BS⁷, Joshua Lawrence, BS⁷, Jillian
- 6 Peters, MD⁵, Andrea Cox, MD², Yukari C. Manabe, MD², Katherine Fenstermacher, PhD⁷,
- 7 Sophia Shea, MPH⁷, Richard E. Rothman, MD, PhD⁷, Bhakti Hansoti, MD⁷, Lauren Sauer, MS⁷,
- 8 Ciprian Crainiceanu, PhD⁶, Danielle V. Clark, PhD¹.
- ⁹Affiliation:
- 10 ¹The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD;
- ² Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD
- ³Division of Pulmonary and Critical Care Medicine, University of Miami, Miami, FL
- ⁴ Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of
- 14 Medicine, Baltimore, MD
- ⁵Division of General Internal Medicine, Johns Hopkins University School of Medicine,
- 16 Baltimore, MD
- ⁶ Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore MD
- 18 ⁷Department of Emergency Medicine, Johns Hopkins University, Baltimore MD.
- 19
- ²⁰*Corresponding Author: Paul W. Blair, MD MSPH MHS. Henry M. Jackson Foundation for the
- 21 Advancement of Military Medicine. 6720A Rockledge Dr, Bethesda, MD 20817. E-mail:
- 22 pblair@aceso-sepsis.org
- 23 **Co-first authors.

- 24 Reprints: Reprints are not being ordered for this manuscript
- 25 Performance institution: Johns Hopkins University School of Medicine
- 26 Financial support: This project was supported by Joint Program Executive Office (JPEO-EB)
- W911QY-20-9-0004 (2020 OTA) and the Johns Hopkins University School of Medicine
- 28 COVID-19 Research Fund.
- Word count: 2,999
- 30 Abstract Word count: 296
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

⁴⁷**Abstract**

⁴⁸**Objective:** The clinical utility of point-of-care lung ultrasound (LUS) for disease severity triage

49 of hospitalized patients with COVID-19 is unclear.

⁵⁰**Design:** Prospective cohort study

⁵¹**Setting:** A large tertiary care center in Maryland, USA between April 2020 to September 2021.

⁵²**Patients:** Hospitalized adults (≥18 years of age) with positive SARS-CoV-2 RT-PCR results.

⁵³**Interventions:** None.

⁵⁴**Measurements and Main Results:** All patients were scanned using a standardized protocol

⁵⁵including 12 lung zones and followed to determine clinical outcomes until hospital discharge and

56 vital status at 28-days. Ultrasounds were independently reviewed for lung and pleural line

57 artifacts and abnormalities, and the mean Lung Ultrasound Score (ranging from 0 to 3) across

58 lung zones (mLUSS) was determined. The primary outcome was time to ICU-level care, defined

59 as high flow oxygen, noninvasive, or mechanical ventilation, within 28-days of the initial

⁶⁰ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for

⁶¹mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the

62 median age was 59 years and 114 (43.2) % of participants were female. The median mLUSS was

63 1 (interquartile range: 0.5 to 1.3). Following enrollment, 29 (11.0%) participants went on to

64 require ICU-level care and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at

65 enrollment was associated with disease progression to ICU-level care (aHR = 3.63 ; 95% CI: 1.23

66 to 10.65) and 28-day mortality (aHR = 4.50; 95% CI: 1.52 to 13.31). Pleural line abnormalities

67 were independently associated with disease progression to ICU-level care (aHR $= 18.86$; CI:

68 1.57 to 226.09).

⁹²**Introduction**

93 Point-of-care lung ultrasound (LUS) has been used for the evaluation of a range of 94 cardiopulmonary conditions in emergency and critical care settings though, to date, 95 implementation protocols have varied across settings. LUS offers benefits over traditional 96 imaging modalities including portability, instantaneous results, lower costs, and lack of exposure 97 to ionizing radiation. LUS has been proposed as an essential tool in evaluating patients with 98 coronavirus disease 2019 (COVID-19) pneumonia to prevent nosocomial spread of disease.(1) ⁹⁹Ultrasound hardware can be cleaned easily and reduces the burden on personnel and resources 100 that would be required for traditional chest imaging. LUS may be able to identify patients at risk 101 for decompensation requiring higher level of care in resource-limited settings or in regions with 102 limited ICU capacity during a COVID-19 surge.

104 Despite the potential utility of LUS in COVID-19 management, standardized and evidence-based 105 clinical use has not been fully established. The most widely studied and reported findings are 106 based on the LUS score, originally developed in 2011 and used for assessment of aeration for 107 titration of positive end-expiratory pressure (PEEP) (2). This scoring system includes a 0 to 3 108 point grade per 6 lung zones totaled from each hemithorax (3). This has been adopted for 109 prognostication for non-COVID-19 acute respiratory distress syndrome (4) and was subsequently 110 evaluated as a part of candidate models for COVID-19 prognostication (5-9). Among individuals 111 with COVID-19, the LUS score has been associated with relevant chest CT findings and predicts 112 the extent of parenchymal disease as well as mortality.(5) However, modified scores have 113 limitations and have not been widely adopted. Modifications to scores had been based on early 114 anecdotal reports and resulted in multiple scoring systems without protocol standardization and

¹¹⁸The aim of this study was to determine the association between baseline lung ultrasound findings 119 and the ultimate oxygen support requirements or death. We used a mean LUS (mLUSS) rather 120 than a sum to determine the utility of the original and most studied LUS score (2) for COVID-19 121 prognostication with the added flexibility to include less than 12 lung zones. We performed a 122 survival analysis with Cox regression mLUSS to determine risk of subsequently requiring ICU-123 level care (i.e., either high flow oxygen, noninvasive, or invasive ventilation) as a primary 124 outcome. Secondary outcomes included ventilation plus 28-day death or 28-day death alone. We 125 hypothesized that the mLUSS would be associated with an increased risk of progression to 126 requiring ICU-level care.

¹²⁸**Methods**

129 We enrolled adults $(\geq 18$ years of age) who tested positive for SARS-CoV-2 on RT-PCR and 130 were admitted to Johns Hopkins Hospital in Baltimore, Maryland into a larger COVID-19 131 prospective cohort after verbal informed consent, between April 2020 to September 2021 as a 132 convenience sample. This protocol was approved by the Johns Hopkins University Institutional 133 Review Board (IRB00245545). Participants were enrolled after admission throughout the 134 enrollment period or from the emergency department starting December 2020. After screening ¹³⁵2,270 patients, 723 participants enrolled into the master protocol, and 264 of these participants 136 had LUS performed as part of study procedures depending on LUS-trained research staff 137 availability.

159 As previously described (13), the LUS score was calculated for each zone with 1 point for 160 discrete B lines, 2 points for coalescent B lines, and 3 points for lung consolidation. The mean

¹⁶¹LUS score (mLUSS) ranges from 0 to 3, with a higher score signifying higher severity. The ¹⁶²mLUSS was calculated out of total available zones to include participants with missing zones. 163 The Pearson correlation coefficient of the mLUSS between masked ultrasound clip readers was 164 determined for the participants that were available (61 consecutive patients or 23% of the 165 cohort). Participants were divided into severity groups at baseline based on severity at the time of 166 POCUS or peak severity prior to POCUS: on room air or nasal cannula supplemental oxygen 167 (moderate disease), on HFNC or noninvasive positive pressure ventilation (NIPPV) (moderately 168 severe), or on mechanical ventilation (severe disease). Summary statistics were performed by ¹⁶⁹comparing baseline demographics (i.e., sex, age, race, ethnicity, medical comorbidities), and 170 duration post symptom-onset between severity groups using Kruskal-Wallis tests. 172 Progression to ICU-level care was defined as newly requiring either high flow nasal cannula, ¹⁷³noninvasive ventilation, or mechanical ventilation during the hospitalization. To determine the 174 association between baseline LUS characteristics and future risk, this outcome was restricted to 175 study participants not requiring more than supplemental oxygen via low-flow nasal cannula at 176 baseline (among those with moderate disease at baseline, $N=164$) (Figure 2). Secondary 177 outcomes included 28-day mortality (all baseline severity groups, $N=264$) and 28-day 178 progression to mechanical ventilation or 28-day death (among those with moderate or 179 moderately severe disease, $N=215$) (Figure 2). A Kaplan-Meier plot was created to compare risk 180 over time between those at the $25th$ and $75th$ mLUSS percentile. After checking the proportional 181 hazards assumption, Cox proportional hazards regression models were used to evaluate the 182 differences in risk of death and risk of death or subsequent mechanical ventilation plus 28-day 183 death as a function of baseline % of lung fields with A lines, % with B lines, % with

¹⁹²**Results**

193 Of 264 participants, the median age was 61 (interquartile range [IQR], 48 to 68 years) and 43.0% 194 $(n = 114)$ were female (Table 1). The study participants were racially and ethnically diverse with 195 47.9% (n=127) of the population identified as black and 16.6% (n = 44) identified as Hispanic. 196 The median time from symptoms onset until ultrasound scan was 9.29 days (IQR, 5.15 to 14.31) 197 days) and the median mLUSS at baseline was 1.00 (IQR, $0.50 - 1.30$) overall. Comorbid illness 198 was common. The majority (74.2%) of participants had hypertension and 42.4% participants had 199 diabetes mellitus (Table 1). Diagnoses of congestive heart failure (33.0%) and chronic 200 obstructive pulmonary disease (36.4%) were also common. Most participants were overweight 201 (median 30.0 kg/m²; IQR: 25.4 to 33.2). At baseline, 169 participants required only ambient 202 oxygen or nasal cannula supplemental oxygen, and an additional 46 participants $(18.7%)$ were 203 requiring high flow nasal cannula (HFNC) or non-invasive positive pressure ventilation ²⁰⁴(NIPPV). (Table 1) Lastly, 40 participants (16.3%) required mechanical ventilation at the time of 205 initial ultrasound scanning. During hospitalization, the most frequent treatments included 206 dexamethasone (63.6% of participants), remdesivir (50.0%) , or tocilizumab (9.1%).

207

²⁰⁸*Baseline cross-sectional differences in POCUS findings by severity*

- 209 At enrollment, participants with severe illness were later in their course of illness (median: 15.79
- 210 days post symptom onset; IQR: 10.92 to 26.70 days) compared to those with moderately severe
- 211 (median: 9.29 days; IQR: 7.03 to 13.92 days), or moderate illness (median 7.38 days; IQR 4.08
- 212 to 11.92 days) (Table 2). A lines were the most common finding among lung zones scanned
- 213 (median 75.0% of lung fields; IQR, 58.3 to 91.7%), with a stepwise decrease in proportion of
- 214 lung zones affected in moderately severe disease (median 69.7%; IQR, 51.8 to 87.1%) followed
- 215 by severe disease at enrollment (54.6%; IQR, 25.0 to 66.7%) (Table 2). B lines were more likely
- 216 to be present among those with severe disease (median 75.0% ; IQR, 60.0 to 100%) or
- 217 moderately severe disease (median 81.8%; IQR, 67.9 to 100%) compared to moderate cases
- ²¹⁸(median 57.1%; IQR, 27.3 to 75.0%). Similarly, participants requiring mechanical ventilation at
- 219 enrollment had higher percent of pleural line abnormalities (median 25.0%; IQR, 9.1 to 50)
- 220 compared to moderately severe (median 0.0% ; 0.0 to 15.6%) or moderate (median 0.0%; IQR
- 221 0.0 to 16.7%) disease. The mLUSS was lower for moderate disease (median 0.83; IQR, 0.33 to
- 222 0.80) compared to a stepwise increase in moderately severe disease (median 1.11; IQR, 1.00 to
- 223 1.50) followed by severe critical disease (1.25; IQR, 1.00 to 1.67). The Pearson correlation
- 224 coefficient of the mLUSS between readers was high at 0.77 among 61 participants with a an
- 225 available matched masked LUS read (Supplemental Figure S1).

226

²²⁷*Risk of disease progression*

228 When evaluating the 28-day risk of progression to severe COVID-19, multiple baseline POCUS

229 parameters were found to be associated with severity progression using Cox proportional hazards

275 radiographic and clinical severity among adults hospitalized with COVID-19. Nouvenne et al.

276 demonstrated B lines, pleural line irregularities and large parenchymal consolidations with 277 correlated with CT findings and oxygen saturation.(14) In a systematic review of 43 studies the 278 presence of focal, multifocal and/or confluent B lines and the presence of pleural irregularities 279 were common among individuals with COVID-19.(15) Mechanistically, the degree and 280 magnitude of LUS abnormalities throughout lung zones reflects the extent of lung disease and is 281 intuitively directly related to severe disease trajectories. In one of the largest studies to date with 282 matched CT scans, LUS compared to CT as a gold standard for severe COVD-19 had an area 283 under the curve of 0.78 (CI 95% 0.68–0.87; $p\Box < \Box$ 0.001).(16) Rubio-Garcia and colleagues 284 examined the LUS among 130 patients with COVID 19 and demonstrated an increased risk of 285 mortality among individuals with a high modified LUS score (HR 5.25, 0.84–32.84) (9). The 286 investigators however did not describe individual features of the LUS such as A lines, B lines 287 and pleural disease and used a high cutoff to optimize sensitivity (9). While other studies have 288 generally used a sum of all 12 lung zones $(5, 8, 9, 17)$, our study found the risk estimates were 289 unchanged when some lung fields were not obtainable due to clinical instability. Our study is 290 consistent with prior publications and provides evidence that LUS can prognosticate hospitalized 291 patients using available lung zones.

293 Adoption of LUS has varied in hospital settings largely a result of lack of familiarity as well as 294 difference in approaches, techniques, and nomenclature (18). However, research personnel in our 295 study were taught lung ultrasound using standardized protocols without prior experience. 296 Ultrasound images were overread by multiple reviewers and correlated well. Most ultrasound 297 operators were research coordinators who had no experience with ultrasound scanning prior to 298 training for this study. This provided standardization of scans and reduced bias related to direct

299 performance by medical caregivers. This suggests that LUS scanning could be expanded to non-300 clinicians, including but not limited to nursing staff, respiratory therapists, or medics in the field. 301 For example, respiratory therapists or nursing staff could routinely perform LUS scans to obtain 302 and document this valuable information, similar to lung auscultation performed at some centers. 303 Alternatively, ultrasound technicians would be well-equipped to perform LUS scans with a 304 standardized read by radiology. While the value of immediate information to a performing 305 clinician should not be ignored or undervalued, extending the expertise of LUS performance to 306 additional healthcare workers would be more scalable than LUS by clinicians alone. ³⁰⁸Biomarker and therapeutic research has identified the importance of phase of disease as indicated 309 by duration of symptoms (19). However, inference was unchanged after adjusting for duration of 310 symptoms or interaction with duration in our Cox regression models. POCUS results appeared to 311 be generalizable regardless of adjustment for days since symptom onset for determining risk of 312 decompensation towards ICU-level care. Change in LUS findings were not evaluated here due to 313 a limited sample size of repeat time events (data not shown), but studies are ongoing to evaluate 314 longitudinal LUS for estimating risk of severe disease and treatment response.

316 There were limitations to the present study. First, not all participants were enrolled prior to 317 admission, and as this was a hospital-based protocol, generally had a minimum requirement of 318 oxygen. Patients were not always enrolled on the day of admission which may have diminished 319 the effect size of differences in POCUS findings. Additionally, those hospitalized with incidental 320 asymptomatic SARS-CoV-2 infection may be less comparable to those with moderate severity, 321 but a sensitivity analysis was performed and inference about risk was unchanged. These factors

- ³⁶⁷7. Alharthy A, Faqihi F, Abuhamdah M, et al: Prospective Longitudinal Evaluation of
- 368 Point-of-Care Lung Ultrasound in Critically Ill Patients With Severe COVID-19 Pneumonia. *J*
- ³⁶⁹*Ultrasound Med* ²⁰²⁰
- 370 8. Ji L, Cao C, Gao Y, et al: Prognostic value of bedside lung ultrasound score in patients
- ³⁷¹with COVID-19. *Crit Care* 2020; 24(1):700
- ³⁷²9. Rubio-Gracia J, Giménez-López I, Garcés-Horna V, et al: Point-of-care lung ultrasound
- 373 assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective
- ³⁷⁴noninterventional study. *Eur Respir J* 2021; 58(3)
- ³⁷⁵10. Soldati G, Smargiassi A, Inchingolo R, et al: Proposal for International Standardization
- 376 of the Use of Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative,
- ³⁷⁷Reproducible Method. *J Ultrasound Med* 2020; 39(7):1413-1419
- ³⁷⁸11. inHealth JH: PMAP: The Johns Hopkins Precision Medicine Analytics Platform.
- 379 Available at: https://pm.jh.edu/. Accessed December 30, 2021
- 380 12. Gryczynski J, Nordeck CD, Martin RD, et al: Leveraging health information exchange
- 381 for clinical research: Extreme underreporting of hospital service utilization among patients with
- 382 substance use disorders. *Drug Alcohol Depend* 2020; 212:107992
- ³⁸³13. Soummer A, Perbet S, Brisson H, et al: Ultrasound assessment of lung aeration loss
- 384 during a successful weaning trial predicts postextubation distress^{*}. *Crit Care Med* 2012;
- ³⁸⁵40(7):2064-2072
- 386 14. Nouvenne A, Zani MD, Milanese G, et al: Lung Ultrasound in COVID-19 Pneumonia:
- ³⁸⁷Correlations with Chest CT on Hospital admission. *Respiration* 2020; 99(7):617-624
- 388 15. Peixoto AO, Costa RM, Uzun R, et al: Applicability of lung ultrasound in COVID-19
- ³⁸⁹diagnosis and evaluation of the disease progression: A systematic review. *Pulmonology* ²⁰²¹

- 390 16. Zieleskiewicz L, Markarian T, Lopez A, et al: Comparative study of lung ultrasound and
- 391 chest computed tomography scan in the assessment of severity of confirmed COVID-19
- ³⁹²pneumonia. *Intensive Care Med* 2020; 46(9):1707-1713
- ³⁹³17. Lichter Y, Topilsky Y, Taieb P, et al: Lung ultrasound predicts clinical course and
- 394 outcomes in COVID-19 patients. *Intensive Care Med* 2020; 46(10):1873-1883
- 395 18. Volpicelli G, Elbarbary M, Blaivas M, et al: International evidence-based
- 396 recommendations for point-of-care lung ultrasound. *Intensive Care Med* 2012; 38(4):577-591
- 397 19. Datta SD, Talwar A, Lee JT: A Proposed Framework and Timeline of the Spectrum of
- 398 Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health
- ³⁹⁹Implications. *JAMA* 2020; 324(22):2251-2252
-
-

- ⁴⁰³**Figure 1**. Lung ultrasound characteristics. 1A: A lines (arrows) are shown indicating normal
- 404 lung aeration; 1B: discrete B lines (arrows), implicating subpleural interstitial edema; 1C: a
- 405 coalesced B line (arrow); 1D: a small pleural effusion (arrow); 1E: fragmented pleural line
- 406 (arrow); 1F: a subpleural consolidation (arrow).
- ⁴⁰⁷**Figure 2.** Flow diagram of enrollments and total participants included in survival analyses.
- **408** Figure 3. Kaplan-Meier time to progression by $75th$ percentile (1.3) vs $25th$ percentile (0.5)
- 409 mLUSS scores from time of lung ultrasound scan.
- ⁴¹⁰**Figure 4.** Forest Plot of hazard ratios of LUS parameters from individually fit models adjusting
- 411 for age and sex for progression to severe disease.
- 412

⁴⁰² Figure legends.

 A

 $sr2I$

 $\mathsf{\Gamma}$

F

 \rightarrow mLUSS = 0.5 \rightarrow mLUSS = 1.3 - Unadjusted

Progression to ICU-level care

 \overline{A}

 $\mathsf C$

Progression to death

Characteristic Total (N=264) Age —years, median (IQR) 58.56 (48.75, 68.00) **Female — no. (%)** 114 (43.18) **Race — no. (%) Asian Black White Other** 7 (2.65) 126 (47.73) 80 (30.30) 49 (18.46) **Ethnicity — no. (%) Hispanic Non-Hispanic** 44 (16.67) 220 (83.33) **Smoking — no. (%) Never Current Former** 149 (56.44%) 23 (8.71%) 80 (30.30%) **Median BMI — kg/m² , median (IQR)** 30.00 (25.4, 33.2) **Comorbidities — no. (%) Cancer Congestive heart failure COPD Diabetes Hypertension HIV/AIDS Liver Disease** 25 (9.5) 87 (33.0) 96 (36.4) 112 (42.4) 196 (74.2) 12 (4.6) 54 (20.5) **Symptoms onset until LUS Scan — days, median (IQR)** 9.29 (5.2, 14.3) **Total lung zones scanned — median (IQR)** 9 (7, 12) **mLUS Score — median (IQR)** 1.00 (0.50, 1.30) **A-line lung fields — %, median (IQR)** 0.75 (0.58, 0.92) **B-line lung fields — %, median (IQR)** 0.67 (0.38, 0.84) **Pleural Line abnormality lung fields — %, median (IQR)** 0.00 (0.00, 0.18)

Table 1. Participant baseline demographics.

NIPPV: Non-invasive positive pressure ventilation; mLUS: mean lung ultrasound score

Table 2. Cross-sectional differences in lung ultrasound findings by severity at baseline.

NIPPV: Non-invasive positive pressure ventilation; mLUS: mean lung ultrasound score †Kruskal-Wallis test by ranks